Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | KLK3 | P07288 | 2/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16184703 | 0.94 | MAPT (0.47) | MAPTKDM4ELMNASMN1; SMN2MKNK1 | |
| SCHEMBL16184768 | 0.89 | MAPT (0.46) | MAPTKDM4ELMNASMN1; SMN2MKNK1 | |
| SCHEMBL16184789 | 0.89 | MAPT (0.46) | MAPTKDM4ELMNASMN1; SMN2MKNK1 | |
| SCHEMBL16184719 | 0.88 | MAPT (0.45) | MAPTKDM4ELMNASMN1; SMN2MKNK1 | |
| SCHEMBL14475242 | 0.88 | MAPT (0.47) | MAPTKDM4ELMNASMN1; SMN2MKNK1 | |
| SCHEMBL16184802 | 0.88 | MAPT (0.46) | MAPTKDM4ELMNASMN1; SMN2MKNK1 | |
| SCHEMBL16184736 | 0.88 | MAPT (0.48) | MAPTKDM4ELMNASMN1; SMN2MKNK1 | |
| SCHEMBL16184753 | 0.86 | MAPT (0.48) | MAPTKDM4ELMNASMN1; SMN2MKNK1 | |
| SCHEMBL16184740 | 0.82 | MAPT (0.37) | MAPTKDM4ELMNASMN1; SMN2MKNK1 | |
| SCHEMBL16184741 | 0.82 | MAPT (0.47) | MAPTKDM4ELMNASMN1; SMN2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | MAPT 509/4885KDM4E 1395/4885LMNA 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.